IC 14

Drug Profile

IC 14

Alternative Names: Anti-CD14 antibody

Latest Information Update: 10 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICOS Corporation
  • Developer ICOS Corporation; Implicit Bioscience; University of Washington
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action CD14 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury
  • Phase I Motor neuron disease
  • Clinical Phase Unknown Adult respiratory distress syndrome
  • Discontinued Septic shock

Most Recent Events

  • 25 Apr 2018 Implicit Bioscience plans a phase II trial for Motor neuron disease in Australia (IV) in August 2018 (NCT03508453)
  • 22 Mar 2018 Implicit Bioscience plans a phase II study for Amyotrophic Lateral Sclerosis in USA in September 2018 (NCT03474263)
  • 01 Oct 2017 Phase-I clinical trials in Motor neuron disease in Australia (IV) (NCT03487263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top